NEIRG
GALT icon

New England Investment & Retirement Group’s Galectin Therapeutics GALT Stock Holding History

New England Investment & Retirement Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17
Closed – – 116
2020
Q1 		$0 Buy
+17
New +$41 ﹤0.01% 212

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

New England Investment & Retirement Group's GALT Position: Q2 2020 in Review

New England Investment & Retirement Group sold out of Galectin Therapeutics (GALT) in Q2 2020, closing a stake of 17 shares.

New England Investment & Retirement Group first reported a position in GALT in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 75 funds tracked by Wall St. Rank hold GALT as of Q2 2020.

  • New England Investment & Retirement Group reported no remaining Galectin Therapeutics position as of Q2 2020 after selling out during the quarter.
  • New England Investment & Retirement Group sold 17 Galectin Therapeutics shares in Q2 2020.
  • New England Investment & Retirement Group first reported a position in Galectin Therapeutics in Q1 2020 and held it in 1 quarter.
  • New England Investment & Retirement Group's Galectin Therapeutics position peaked at $0 in Q1 2020.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2020.

Based on New England Investment & Retirement Group's 13F filing for Q2 2020, filed 3 Aug 2020.